UCSD - University of California - San Diego

10/06/2026 | Press release | Distributed by Public on 10/06/2026 11:26

Contrary to Fears, Psilocybin Users with Depression Continue to Seek Treatment

Published Date

October 06, 2026

Article Content

In a nationally representative study on psilocybin use and mental health treatment, researchers at the University of California San Diego School of Medicine have found that among people with depression, those who use psilocybin pursue mental health care at similar rates to nonusers. However, they report higher unmet needs for mental health care services, suggesting that while people may seek out psilocybin as an alternative or adjunct to traditional therapy, they are not looking to replace it entirely. The results are published online in the journal Psychological Medicine.

"Our main takeaway is that among people with depression, those using psilocybin aren't abandoning conventional mental health care, which is good news," said Avery Eun, first author of the study and second-year medical student at UC San Diego School of Medicine. "But what is interesting is that even though they use mental health care at the same rate as nonusers, they still feel that their needs aren't being met, which gives us an opportunity to better understand those unmet needs so we can help these patients."

As psilocybin decriminalization gains momentum across the U.S., concerns have grown among mental health care professionals that individuals may forgo supervised mental health care in favor of self-medicating with psilocybin. Until now, there were no nationally representative studies to determine if this trend was actually occurring among those with depression.

In the new study, the researchers analyzed data from the 2024 National Survey on Drug Use and Health (NSDUH), the first iteration of the survey to specifically track the recency of psilocybin use in addition to its prevalence.

"It is one thing to know if someone has used psilocybin at any point in their life, but knowing they used it within the past year allows us to see how that use actually relates to their current engagement with mental health care," added Eun.

The study analyzed data from 6,793 individuals aged 12 and older with a past-year major depressive episode.

Key findings include:

  • An estimated 7.3% of individuals who experienced a major depressive episode in the past year reported using psilocybin during that same period.
  • Psilocybin use was not associated with lower utilization of outpatient, inpatient or telehealth treatment, nor was it linked to a decrease in the use of prescription medications for depression.
  • Psilocybin users reported a significantly higher perceived unmet need for mental health treatment (52.0%) compared to nonusers (33.9%).
  • Psilocybin users were more likely to be younger, male, never married and employed full-time.
"It's really important for providers to interpret psilocybin use in their patients differently. Rather than assuming a patient is retreating from care, providers can use this as a way to start a conversation about the motivations for use. If psilocybin is being used for therapeutic reasons, it may be an opportunity to discuss whether the patient feels their needs are being met by conventional care and what can be done to help if not." - Avery Eun

While randomized controlled trials have shown psilocybin-assisted therapy to be effective in highly monitored clinical settings - featuring structured dosing and psychological support - the researchers emphasize that "naturalistic" use occurs without these safeguards. Because users often obtain the substance from inconsistent sources without clinical monitoring, the safety and efficacy seen in trials may not generalize to those using it on their own.

The new study suggests that the gap between perceived need and actual treatment receipt may drive some individuals toward self-directed symptom management with psychedelics, but the researchers emphasize that it would take further research to prove this hypothesis.

The researchers also note that policy changes, such as decriminalization, may improve patient safety by reducing stigma and creating a safer environment for individuals to share their experiences with providers.

"It's really important for providers to interpret psilocybin use in their patients differently," said Eun. "Rather than assuming a patient is retreating from care, providers can use this as a way to start a conversation about the motivations for use. If psilocybin is being used for therapeutic reasons, it may be an opportunity to discuss whether the patient feels their needs are being met by conventional care and what can be done to help if not."

Read the full study: Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression

Additional authors of the study include Kevin H. Yang, MD, at the University of California, Los Angeles, and Joseph J. Palamar, PhD, at New York University.

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health (Award Numbers R21DA060362 and R01DA057289).

Disclosures: Palamar has consulted for the Washington-Baltimore High Intensity Drug Trafficking Areas program. The authors declare no other potential conflicts of interest.

Read more news about: School of Medicine, Health Sciences

UCSD - University of California - San Diego published this content on October 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 06, 2026 at 17:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]